DrugPatentWatch Database Preview

Details for Patent: 8,372,872

Which drugs does patent 8,372,872 protect, and when does it expire?

Patent 8,372,872 protects ULORIC and is included in one NDA.

This patent has thirteen patent family members in eleven countries.

Summary for Patent: 8,372,872

Title:	Methods for concomitant treatment of theophylline and febuxostat
Abstract:	Co-administration of febuxostat and theophylline to a hyperuricemic patient suffering from gout is disclosed.
Inventor(s):	Gunawardhana; Lhanoo (Pleasant Prairie, WI), Naik; Himanshu (Evanston, IL), Tsai; Max (Highland Park, IL)
Assignee:	Takeda Pharmaceuticals U.S.A., Inc. (Deerfield, IL)
Application Number:	13/295,696
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,372,872
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,372,872

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-001	Feb 13, 2009		RX	Yes	No	➤ Sign Up	➤ Sign Up				USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE	➤ Sign Up
Takeda Pharms Usa	ULORIC	febuxostat	TABLET;ORAL	021856-002	Feb 13, 2009		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 8,372,872

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
9,107,912	Methods for concomitant treatment of theophylline and febuxostat	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 8,372,872

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Russian Federation	2013109380	➤ Sign Up
South Korea	101797936	➤ Sign Up
South Korea	20130097775	➤ Sign Up
Japan	5978216	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,372,872

For more information try a trial or see the plans and pricing